Meet
Ahmed Belghith

Senior Associate

Ahmed Belghith supports biopharmaceutical manufacturers by conducting research and synthesizing findings across diverse health policy issues.

Before joining Avalere, Ahmed worked as a research fellow in the National Institute of Allergy and Infectious Diseases at the National Institutes of Health, where he focused on virology and immunology, including developing a novel, nanoparticle monkeypox vaccine.

Previously, Ahmed worked as an analyst at the Public Health Institute where he advised nonprofit hospitals and community health organizations on aligning their assets with community needs. He also served as a research assistant in the University of North Carolina School of Medicine examining the genetic drivers of heart disease, and as a medical assistant in a rural primary care clinic where he administered vaccinations and supported care delivery.

Ahmed holds a BS in biology with minors in neuroscience and chemistry from the University of North Carolina at Chapel Hill.

Authored Content


The next cohort of drugs includes additional cancer and chronic disease therapies, as well as products that were therapeutic alternatives for IPAY 2026 drugs.

CMS released the rationale for the maximum fair prices under the Medicare Drug Price Negotiation Program for Year 1 drugs.

A new Avalere analysis reaffirms 2021 findings that first identified variability in Medicaid physician office and pharmacy vaccine reimbursement policies.